Outset Medical, Inc.
NASDAQ:OMMedical - Devices
+$0.73 today
- Market cap
- $54.86M
- Beta
- 1.94
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$4.07
Volume 0.08M
Average 0.16M
Returns on capital
Outset Medical, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-64.3%
avg -98.1%
ROIC
-29.2%
avg -48.1%
ROA
-30.9%
avg -42.7%
Analysis
ROIC is currently the strongest return metric at -29.2% versus its period average of -48.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Leslie L. Trigg | President, Chief Executive Officer & Chairman | USD 1.06M | 55 | — | — |
John L. Brottem | General Counsel & Secretary | USD 566.09K | 52 | 87.47K | 0.47% |
Renee Gaeta | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer | USD 336.05K | 45 | 180.84K | 0.98% |
Michael Aragon | Chief Medical Officer | — | — | — | — |
Brett Fogg | Senior Vice President of R&D & Operations | — | — | — | — |
Derick Elliott | Executive Vice President of Commercial | — | — | — | — |
Jaime Pulido | Senior Vice President of Finance | — | — | — | — |
Sara Mueller | Vice President of Marketing & Sales Effectiveness | — | — | — | — |
Brittni McGill | Chief Nursing Officer | — | — | — | — |
Amelia Merrill | Vice President of People Operations & Culture | — | 54 | — | — |
Dinamarie Stefani | Senior Vice President of Regulatory Affairs & Quality Assurance | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 17, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$870,260.40
Sells
20
$362,052.07
Net Transaction Value
+$508,208.33
Net buying
Most Active
Trigg Leslie
6 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 2, 26Oct 2, 2026 | Leonard Braden Michael Indirect | Buy | $64.2K$64,241.39 |
| Oct 1, 26Oct 1, 2026 | Leonard Braden Michael Indirect | Buy | $806K$806,019.02 |
| Aug 17, 26Aug 17, 2026 | Trigg Leslie Direct | Sell | $15.1K$15,088.43 |
| Aug 17, 26Aug 17, 2026 | Brottem John L. Direct | Sell | $11.6K$11,554.48 |
| Aug 17, 26Aug 17, 2026 | Gaeta Renee Direct | Sell | $19.9K$19,943.77 |
| Jun 3, 26Jun 3, 2026 | Gaeta Renee Direct | Sell | $87.3K$87,299.68 |
| May 15, 26May 15, 2026 | Trigg Leslie Direct | Sell | $12.7K$12,746.50 |
| May 15, 26May 15, 2026 | Nash Marc Direct | Sell | $5.9K$5,853.40 |
| May 15, 26May 15, 2026 | Brottem John L. Direct | Sell | $9.8K$9,760.60 |
| Feb 17, 26Feb 17, 2026 | Brottem John L. Direct | Sell | $9.5K$9,520.70 |
1–10 of 22
Summary
Insiders reported 2 buys worth $870,260.40 and 20 sells worth $362,052.07 over the last 12 months. That adds up to net buying of $508,208.33. Trigg Leslie was the most active insider with 6 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +1.2% | +10.2% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +1.2% over three years. Forward estimates point to Revenue at +10.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Outset Medical, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about OM's management, answered from reported figures.
Who manages OM?
Outset Medical, Inc. (OM) lists 11 active executives. The top listed executive is Michael Aragon, Chief Medical Officer.
Are OM insiders buying or selling?
Recent insider activity shows net buying of $1.96M.
Continue the stock analysis
Jump to another research area for this company.